Combivir Information

What's inside Combivir

Combivir in the News

CROI: HAART use in mothers substantially reduces HIV infections in ... - Aidsmap
From July 2003 to January 2005, the HAART regimens consisted of Combivir (300 mg zidovudine / 150 mg lamivudine) twice daily, plus nevirapine. ...
Tue Feb 05 14:02:07 -0500 2008

Maraviroc-Based Antiretroviral Treatment Appears Neutral in ... - DG News
... (Combivir) than for those receiving maraviroc plus Combivir," said Edwin DeJesus, MD, Medical Director, Orlando Immunology Center, Orlando, Florida. ...
Wed Feb 06 16:57:48 -0500 2008

Switching From Zidovudine- to Tenofovir-Based Therapy Preserves ... - DG News
By Maria Bishop BOSTON, MA -- February 6, 2008 -- Patients with HIV who switch from a combination of zidovudine and lamivudine (Combivir) to tenofovir plus ...
Wed Feb 06 18:37:58 -0500 2008

Combivir Chemical Information

lamivudine - A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)

zidovudine - A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)